This in-vitro-growth-derived composite molecular profile NRAS/CBL/EZH2 improves the predictive power over single molecular parameters in patients with CMML, and therefore could be useful for managing patients with this malignancy. The gene discussed is EZH2; the disease is chronic myelomonocytic leukemia.